A detailed history of Jacob Asset Management Of New York LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Jacob Asset Management Of New York LLC holds 4,247 shares of KRYS stock, worth $673,234. This represents 0.7% of its overall portfolio holdings.

Number of Shares
4,247
Previous 4,647 8.61%
Holding current value
$673,234
Previous $545,000 9.72%
% of portfolio
0.7%
Previous 0.62%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 01, 2023

SELL
$108.51 - $130.22 $43,404 - $52,088
-400 Reduced 8.61%
4,247 $492,000
Q2 2023

Aug 10, 2023

SELL
$78.48 - $130.32 $205,539 - $341,308
-2,619 Reduced 36.04%
4,647 $545,000
Q1 2023

May 11, 2023

BUY
$72.39 - $84.27 $23,816 - $27,724
329 Added 4.74%
7,266 $581,000
Q4 2022

Feb 14, 2023

BUY
$63.14 - $79.9 $200,469 - $253,682
3,175 Added 84.4%
6,937 $549,000
Q3 2022

Nov 10, 2022

SELL
$64.85 - $82.4 $62,580 - $79,516
-965 Reduced 20.41%
3,762 $262,000
Q2 2022

Aug 11, 2022

SELL
$48.93 - $73.47 $1.44 Million - $2.17 Million
-29,515 Reduced 86.2%
4,727 $310,000
Q1 2022

May 12, 2022

SELL
$51.99 - $72.11 $867,193 - $1.2 Million
-16,680 Reduced 32.76%
34,242 $2.28 Million
Q4 2021

Feb 09, 2022

BUY
$39.81 - $88.24 $1.03 Million - $2.28 Million
25,878 Added 103.33%
50,922 $3.56 Million
Q3 2021

Nov 12, 2021

BUY
$52.01 - $71.77 $423,569 - $584,494
8,144 Added 48.19%
25,044 $1.31 Million
Q1 2021

Oct 04, 2021

BUY
$59.42 - $85.46 $415,940 - $598,220
7,000 Added 70.71%
16,900 $1.3 Million
Q4 2020

Oct 04, 2021

BUY
$40.64 - $61.38 $402,336 - $607,662
9,900 New
9,900 $594,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.07B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Jacob Asset Management Of New York LLC Portfolio

Follow Jacob Asset Management Of New York LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacob Asset Management Of New York LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jacob Asset Management Of New York LLC with notifications on news.